8-KRegulation FDExhibits & Filings

Medtronic plc 8-K Report, Regulation FD Disclosure (Feb 17, 2015)

Filed February 17, 2015For Securities:MDT

Summary

Medtronic plc (MDT) filed an 8-K on February 17, 2015, primarily to furnish a press release announcing its third quarter fiscal year 2015 financial results. Notably, this report clarifies that the reported financial results are for Medtronic, Inc. and do not yet include the operations of Covidien plc, as the acquisition was not yet closed. The financial period ending January 23, 2015, predates the consolidation of Covidien. Investors should note that the first financial reporting period that will reflect the combined entity of Medtronic plc, Medtronic, Inc., and Covidien plc as subsidiaries will be for the quarter ending April 24, 2015. This distinction is crucial for understanding the company's reported performance and for forecasting future financial statements as they will reflect the significant impact of the Covidien acquisition.

Key Highlights

  • 1Medtronic plc filed an 8-K on February 17, 2015, to report its Q3 FY2015 financial results.
  • 2The reported Q3 FY2015 results pertain to Medtronic, Inc. only, prior to the closing of the Covidien acquisition.
  • 3The acquisition of Covidien plc was not yet completed as of the reporting date (February 17, 2015).
  • 4The first financial reporting period to include the combined results of Medtronic and Covidien will be the quarter ending April 24, 2015.
  • 5The press release announcing these results is furnished as Exhibit 99.1 to the 8-K filing.

Frequently Asked Questions

The financial results for the quarter ending April 24, 2015, will be the first period to include the combined operations of Medtronic and Covidien plc, as subsidiaries of Medtronic plc. The results reported in this 8-K filing for the quarter ended January 23, 2015, do not include Covidien.

This filing is important for investors to understand that the Q3 FY2015 financial results being reported are only for Medtronic, Inc., and do not yet reflect the impact of the significant acquisition of Covidien. This clarifies the standalone performance of Medtronic prior to the integration of Covidien.

This 8-K filing primarily reports on Medtronic's third quarter of fiscal year 2015, which ended on January 23, 2015. However, it is crucial to note that these are the results for Medtronic, Inc. prior to the completion of the Covidien acquisition.